The Effects of Upper Airway and Digestive Tract Tumors on the Immune System
NCT00001603 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93
Last updated 2008-03-04
Summary
The goal of this study is to learn how tumors of the upper airway and digestive passages (tongue, throat, mouth, and voicebox) affect the body's immune defenses and energy storage.
Previous studies have shown that tumors of the vocal tract produce signals that could help the tumor escape the body's immune defenses and use the body's energy and mineral stores to grow.
Researchers are hoping to learn more about what signals give tumor cells an advantage to live and grow, how tumor cells control these signals, and how these signals affect the rest of the body. This study will look closer at researchers belief that tumors in the vocal tract contain genes (genetic information) that abnormally function to allow the tumors to survive and grow against the attack of the body's normal immune system
Patients with cancerous tumors (squamous cell carcinoma) and benign (non-cancerous) tumors (papilloma) of the upper aerodigestive tract who are candidates for standard or investigational therapy are eligible to participate in this study.
Tumor cells will be collected from patients participating in the study, who will undergo standard surgical treatment or biopsies for their conditions. Once tumor cells are collected they can be analyzed for their genetic make-up.
In addition, patients will undergo several tests using skin, blood, and urine to look closely at the function of their immune systems and metabolism.
Conditions
- Esophageal Neoplasm
- Head and Neck Neoplasm
- Laryngeal Neoplasm
- Papilloma
- Squamous Cell Carcinoma
Sponsors & Collaborators
-
National Institute on Deafness and Other Communication Disorders (NIDCD)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 1996-12-31
- Completion
- 2004-12-31
Countries
- United States
Study Locations
More Related Trials
-
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
NCT00609219 ·Status: COMPLETED ·Phase: PHASE1
-
TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
NCT02065362 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
NCT03515252 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT04162158 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT02496273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)
NCT01671592 ·Status: COMPLETED ·Phase: PHASE1
-
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
NCT05317325 ·Status: UNKNOWN ·Phase: PHASE1
-
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
NCT02280811 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer
NCT02693236 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Dendritic Cell Vaccine for Head and Neck Cancer
NCT00492947 ·Status: WITHDRAWN ·Phase: PHASE1
-
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00128622 ·Status: COMPLETED ·Phase: PHASE1
-
Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor
NCT00377247 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Efficacy of γδ T Cell Against Gastric Cancer
NCT02585908 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT03282617 ·Status: UNKNOWN ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00023985 ·Status: COMPLETED ·Phase: PHASE1
-
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
NCT01235845 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
NCT00057915 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
NCT00103116 ·Status: COMPLETED ·Phase: PHASE2
-
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
NCT02858310 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)
NCT02425748 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors
NCT04765462 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
NCT00405327 ·Status: COMPLETED ·Phase: PHASE2
-
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
NCT00521287 ·Status: UNKNOWN ·Phase: PHASE2
-
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
NCT04665388 ·Status: RECRUITING